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Abstract
Background: MicroRNAs are small RNA species that regulate gene expression post-transcriptionally and are
aberrantly expressed in many cancers including hematological malignancies. However, the role of microRNAs in
the pathogenesis of multiple myeloma (MM) is only poorly understood. We therefore used microarray analysis to
elucidate the complete miRNome (miRBase version 13.0) of purified tumor (CD138+) cells from 33 patients with
MM, 5 patients with monoclonal gammopathy of undetermined significance (MGUS) and 9 controls.
Results: Unsupervised cluster analysis revealed that MM and MGUS samples have a distinct microRNA expression
profile from control CD138+ cells. The majority of microRNAs aberrantly expressed in MM (109/129) were up-regulated.
A comparison of these microRNAs with those aberrantly expressed in other B-cell and T-cell malignancies revealed a
surprising degree of similarity (~40%) suggesting the existence of a common lymphoma microRNA signature. We
identified 39 microRNAs associated with the pre-malignant condition MGUS. Twenty-three (59%) of these were also
aberrantly expressed in MM suggesting common microRNA expression events in MM progression. MM is characterized
by multiple chromosomal abnormalities of varying prognostic significance. We identified specific microRNA signatures
associated with the most common IgH translocations (t(4;14) and t(11;14)) and del(13q). Expression levels of these
microRNAs were distinct between the genetic subtypes (by cluster analysis) and correctly predicted these abnormalities
in > 85% of cases using the support vector machine algorithm. Additionally, we identified microRNAs associated with
light chain only myeloma, as well as IgG and IgA-type MM. Finally, we identified 32 microRNAs associated with event-
free survival (EFS) in MM, ten of which were significant by univariate (logrank) survival analysis.
Conclusions: In summary, this work has identified aberrantly expressed microRNAs associated with the diagnosis,
pathogenesis and prognosis of MM, data which will prove an invaluable resource for understanding the role of
microRNAs in this devastating disease.
Reviewers: This article was reviewed by Prof. Neil Smalheiser, Prof. Yuriy Gusev, and an unknown reviewer.
Background
Multiple myeloma (MM) is a plasma cell (PC) malig-
nancy with an annual incidence of over 14,000 cases in
the US alone. MM is essentially an incurable disease
with a median survival of ~3 years that accounts for
nearly 2% of deaths from cancer and about 20% of
deaths from hematological cancers [1]. Newer therapies,
however, are resulting in improvements in the median
survival [2]. Recent advances in molecular and genetic
research have lead to the realization that MM, although
defined histologically as a single entity, encompasses a
wide range and frequently complex mixture of genomic
abnormalities which differ in both their molecular
pathogenesis and prognostic significance. The recent
discovery of short non-coding RNA molecules that regu-
late gene expression post-transcriptionally, known as
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microRNAs, represent yet another level of complexity in
our understanding of gene regulation and as such could
further our understanding of the pathogenesis of MM.
MicroRNAs have been demonstrated to have diagnos-
tic and prognostic potential in cancer [3-7] and it has
been suggested that microRNA expression profiling can
distinguish cancers according to both the cellular nature
and the developmental stage of the tumor with a greater
degree of accuracy than traditional gene expression ana-
lysis [8]. There is increasingly strong evidence that
microRNAs are involved in the pathogenesis of many
cancers including B and T cell lymphomas [9,10]. There
is however little known about the role that microRNAs
play in MM.
Therefore we undertook a comprehensive study using
microarray technology to elucidate the complete miR-
Nome (miRBase version 13.0) of purified tumor (CD138
+) cells from the bone marrow of 33 MM and 5 MGUS
patients (and 9 controls). In order to investigate micro-
RNA expression in different genetic subtypes MM cases
were classified cytogenetically by FISH. These data were
then correlated with genetic subtype and clinical
parameters.
Results
Most aberrantly expressed microRNAs associated with
MM are up-regulated
We elucidated the complete (miRBase v.10.1) microRNA
profile of CD138+ plasma B-cells from bone marrow of
33 MM patients, 5 MGUS, 9 controls, and 4 well estab-
lished MM cell lines (NCI-H929, JJN3, Thiel and RPMI-
8226). Unsupervised cluster analysis revealed that MM
samples and MM cell lines have a distinct microRNA
profile from counterpart controls (Figure 1A). Further-
more, although MGUS samples did not cluster together,
they had a microRNA profile more similar to MM sam-
ples (and cell lines) than controls.
To identify microRNAs that are aberrantly expressed
in MM patient samples we compared expression levels
with controls by ANOVA. This resulted in the identifi-
cation of 129 microRNAs (P < 0.05), only 20 (15%) of
which were down-regulated in MM samples (Table 1).
Of these 29 and 24 were previously identified as being
aberrantly expressed in MM by the studies of Zhou et
al [11] and Pichiorri et al [12] respectively. In order to
validate the microarray data, eight microRNAs chosen
for their previous association with MM or other hema-
tological malignancies were measured by qRT-PCR.
These data were consistent with the microarray results
(Figure 2). Many microRNAs are encoded in clusters,
and members of these clusters often exhibit the same
pattern of expression [13]. A lower proportion of MM-
associated microRNAs (42/109 (38%); Table 1) were
encoded in clusters than generally observed (215/474
(45%)) (source- http://www.diana.pcbi.upenn.edu/cgi-
bin/miRGen/v3/Cluster.cgi).
Expression levels of the 129 MM-associated micro-
RNAs were distinct between MM and control samples
(Additional file 1 Figure S1). Indeed using only expres-
sion levels of the ten most discriminatory (by P-value)
up- and down-regulated microRNAs distinguished sam-
ples by cluster analysis (Figure 1B) and correctly pre-
dicted samples as either MM or control for 36/41 (88%)
samples using the leave-one-out cross-validation support
vector machine (SVM) algorithm.
The microRNA profile of MGUS patient samples is distinct
from MM and controls
MGUS is generally believed to represent a pre-malig-
nant form of MM [14]. To examine microRNA expres-
sion in this condition we initially compared the profile
of PC cells from MGUS patients with that of controls.
Thirty-nine microRNAs were identified as being
Figure 1 The microRNA expression profile of MM is distinct
from counterpart normal plasma cells. (A) Unsupervised cluster
analysis of microRNA expression data for MM (n = 33), control (n =
9) and MGUS (n = 5) samples. (B) Heat map depicting expression
levels of 10 most discriminatory up- and down-regulated microRNAs
(Table 1) between MM and control samples.
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Table 1 MicroRNAs differentially expressed (P < 0.05) between MM (n = 33) and controls (n = 9) depicting
chromosomal location and where relevant their expression within a microRNA cluster.
Order microRNA adj. P value Fold change Chromosome Cluster
1 miR-1 5.41E-06 3.15 20q13.33/18q11.2 1-1, 133a
2 miR-203 2.09E-05 2.64 14q32.33 -
3 miR-342 2.25E-05 3.94 14q32.2 -
4 miR-631 2.25E-05 4.24 15q24.2 -
5 miR-200a 3.17E-05 5.50 12p13.31 141-200c
6 miR-34c 5.95E-05 3.31 11q33.1 34b-34c
7 miR-361 5.95E-05 12.66 Xq21.2 -
8 miR-9* 7.64E-05 4.48 1q22/5q14.3/15q26.1 -
9 miR-200b 8.52E-05 4.97 12p13.31 141-200c
10 miR-9 8.52E-05 5.07 1q22/5q14.3/15q26.1 -
11 miR-151 1.19E-04 2.67 8q24.3 -
12 miR-218 1.42E-04 3.96 4p15.31/5q34 -
13 miR-28-3p 1.90E-04 2.52 3q28 -
14 miR-200c 2.10E-04 5.26 12p13.31 141-200c
15 miR-21 2.72E-04 2.45 17q23.1 -
16 miR-378 2.72E-04 2.96 5q33.1 -
17 miR-548d-5p 2.72E-04 3.10 8q24.13/17q24.2 -
18 miR-621 2.72E-04 9.64 13q14.11 -
19 miR-140-5p 3.91E-04 2.78 16q22.1 -
20 miR-634 4.77E-04 2.25 17q24.2 -
21 miR-616 6.16E-04 2.69 12q13.3 -
22 miR-130a 7.81E-04 2.48 11q12.1 -
23 miR-593 7.81E-04 3.29 7q32.1 -
24 miR-708 7.81E-04 3.32 11q14.1 -
25 miR-200a* 7.81E-04 4.08 12p13.31 141-200c
26 miR-340 9.03E-04 2.41 5q35.3 -
27 miR-760 1.12E-03 2.44 1p22.1 -
28 miR-885-3p 1.39E-03 2.55 3p25.3 -
29 miR-590-3p 1.42E-03 3.50 7q11.23 -
30 miR-885-5p 1.61E-03 3.34 3p25.3 -
31 miR-221 2.36E-03 2.85 Xp11.3 221-222
32 miR-7 2.36E-03 3.66 9q21.32/15q26.1/19p13.3 -
33 miR-188-5p 2.94E-03 2.18 Xp11.23 532-660
34 miR-338 2.94E-03 2.35 17q25.3 338-657
35 miR-222 2.94E-03 2.47 Xp11.3 221-222
36 miR-99a 2.94E-03 3.47 19q13.33 99b-125a
37 miR-891a 3.06E-03 2.31 Xq27.3 890-891
38 miR-452 3.77E-03 2.57 Xq28 452-224
39 miR-98 4.09E-03 3.04 Xp11.22 98-let-7f
40 miR-629 4.09E-03 3.14 15q23 -
41 miR-515-3p 4.11E-03 5.90 Xq27.3 -
42 miR-192 4.20E-03 2.44 11q13.1 192-194
43 miR-454 4.36E-03 2.82 17q22 -
44 miR-151-3p 4.59E-03 2.22 8q24.3 -
45 miR-141 5.20E-03 3.37 12p13.31 141-200c
46 miR-128b 5.35E-03 2.25 2p21.3/3p22.3 -
47 miR-1227 5.64E-03 2.82 19p13.3 -
48 miR-128a 6.51E-03 2.82 2p21.3/3p22.3 -
49 miR-205 6.94E-03 3.15 1q32.2 -
50 miR-27b 7.30E-03 2.81 9q22.32 23b-24
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Table 1 MicroRNAs differentially expressed (P ?<? 0.05) between MM (n = 33) and controls (n = 9) depicting chromo-
somal location and where relevant their expression within a microRNA cluster. (Continued)
51 miR-608 7.67E-03 2.38 10q24.31 -
52 miR-432 7.99E-03 2.41 14q32.2 337-136
53 miR-220 8.08E-03 2.86 Xq25 -
54 miR-135a 8.30E-03 2.80 3p21.1/12q23 -
55 miR-34a 8.42E-03 2.58 1p36.22 -
56 miR-28 8.72E-03 1.94 3q28 -
57 miR-412 9.41E-03 2.12 14q32.2 323-656
58 miR-877 9.84E-03 1.91 6p21.33 -
59 miR-628-5p 1.04E-02 2.09 15q21.3 -
60 miR-532-3p 1.06E-02 1.95 19q13.41 -
61 miR-625 1.15E-02 2.11 14q23.3 -
62 miR-34b 1.19E-02 2.07 11q33.1 34b-34c
63 miR-31 1.28E-02 2.62 9p21.3 -
64 miR-181a 1.46E-02 2.05 1q32.1/9q33.3 181a-181b
65 miR-32 1.46E-02 2.80 9q31.3 -
66 miR-106b 1.51E-02 2.48 7q22.1 106b-25
67 miR-146a 1.52E-02 2.14 5q33.3 -
68 miR-210 1.52E-02 2.87 11p15.5 -
69 miR-499-5p 1.54E-02 6.60 20q11.2 -
70 miR-140 1.58E-02 2.35 16q22.1 -
71 miR-188 1.68E-02 1.99 Xp11.23 532-660
72 miR-610 1.68E-02 2.54 11p14.1 -
73 miR-27a 1.70E-02 2.45 19p13.12 24-23a
74 miR-142-5p 1.70E-02 2.47 17q22 -
75 miR-603 1.75E-02 1.80 10p12.2 -
76 miR-660 1.75E-02 2.13 Xp11.23 532-502
77 miR-19a 1.75E-02 2.79 13q31.3/Xq26.2 17-92/106a-363
78 miR-649 1.78E-02 1.91 22q11.21 -
79 miR-140-3p 1.98E-02 2.12 16q22.1 -
80 miR-300 2.00E-02 2.30 14q32.31 543-655
81 miR-335 2.11E-02 2.11 7q32.2 -
82 miR-206 2.20E-02 1.84 6p12.2 206-133b
83 miR-20b 2.20E-02 2.18 13q31.3/Xq26.2 17-92/106a-363
84 miR-130b 2.25E-02 2.19 22q11.21 301b-130b
85 miR-183 2.40E-02 2.50 7q32.2 183-182
86 miR-652 2.44E-02 2.36 Xq22.3 -
87 miR-133b 2.44E-02 2.41 6p12.2 133b-206
88 miR-191* 2.56E-02 1.97 3p21.31 425-191
89 miR-19b 2.58E-02 2.62 13q31.3/Xq26.2 17-92/106a-363
90 miR-212 2.71E-02 1.97 17p13.3 212-132
91 miR-194 2.73E-02 2.09 1q41/11q13.1 215-194/192-194
92 miR-100 2.82E-02 2.82 11q24.1 100-let7a
93 miR-1234 2.88E-02 1.91 8q24.3 -
94 miR-182 2.96E-02 2.29 7q32.2 183-182
95 miR-888 3.28E-02 2.15 5q33.1 -
96 miR-30e-5p 3.55E-02 2.27 1p34.2 30e-30c
97 miR-574 3.60E-02 2.16 4p14 -
98 miR-135b 3.60E-02 2.31 1q32.1 -
99 miR-125b 3.60E-02 2.43 11q24.1/21q21 -
100 miR-502 3.77E-02 1.79 Xp11.23 500-502
101 miR-320 3.77E-02 1.74 8p21.3 -
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aberrantly expressed in MGUS samples (P < 0.05; Addi-
tional file 1 Table S3); 28 microRNAs were up-regulated
and 11 down-regulated. Nine of these were consistent
with a previous study [12], including up-regulation of
miR-21, the most up-regulated microRNA identified
(10.3 fold change; Figure 2A), miR-222 and miR-342
(Figure 2E, H respectively), and down-regulation of
miR-200b (Figure 2F). Expression levels of MGUS-asso-
ciated microRNAs distinguished between MGUS and
controls by cluster analysis (Additional file 1 Figure S2),
and correctly predicted 12/13 (92%) the presence of this
disorder by SVM analysis.
Different genetic subtypes of MM have distinct microRNA
expression profiles
Recently it has become increasingly clear that MM dis-
plays an enormous genomic complexity that underlies
the clinical heterogeneity observed with this disease.
The presence of recurrent chromosomal abnormalities
such as IgH translocations and del(13q) have been
shown to have prognostic significance in multiple stu-
dies and as a consequence cytogenetic classification is
increasingly being used to stratify MM patients in clini-
cal practice although not yet routinely [15,16]. In order
to investigate microRNA expression in the different
genetic subtypes of MM, twenty-six cases (for which
there was sufficient material) were cytogenetically classi-
fied using the micro-FISH technique [17]. Individual
patient karyotype data are summarized in Additional file
1 Table S1. Fourteen of 26 (54%) of MM cases harbored
an IgH translocation and 7/26 (27%) exhibited the 13q
(RB) deletion. Of the translocation group eight (57%)
displayed the t(11;14) translocation, three (21%) cases
the t(4;14) translocation, and three cases had an IgH
translocation with an un-known (tested) fusion partner.
Ten (38%) MM patients had no detectable chromosomal
abnormality using our FISH probe sets, although it is
probable that these cases had undetected abnormalities.
The majority of MM tumors harbor IgH transloca-
tions, the most common fusion partners being 11q13
Table 1 MicroRNAs differentially expressed (P ?<? 0.05) between MM (n = 33) and controls (n = 9) depicting chromo-
somal location and where relevant their expression within a microRNA cluster. (Continued)
102 miR-421 3.77E-02 1.76 Xq13.2 421-374b
103 miR-129-3p 3.77E-02 1.80 7q32.1/11p11.2 -
104 miR-190b 4.03E-02 2.02 1q21.3 -
105 miR-18a 4.44E-02 2.21 13q31.3/Xq26.2 17-92/106a-363
106 miR-549 4.44E-02 2.25 15q25.1 -
107 miR-338-5p 4.45E-02 1.97 17q25.3 338-657
108 miR-576-3p 4.60E-02 4.80 4q25 -
109 miR-133a 4.62E-02 2.32 6p12.2 133b-206
-1 miR-373* 1.39E-03 -1.82 19q13.42 371-373
-2 miR-378* 2.43E-03 -3.34 5q33.1 -
-3 miR-143 8.83E-03 -1.80 5q33.1 -
-4 miR-15a 1.51E-02 -1.67 13q14 15a-16
-5 miR-337 1.52E-02 -1.65 14q32.2 493-432
-6 miR-223 1.54E-02 -3.82 Xq12 -
-7 miR-369-3p 1.55E-02 -1.83 14q32.31 323-656
-8 miR-520g 1.58E-02 -1.90 19q13.42 517-518
-9 miR-485-5p 1.75E-02 -3.18 19q13.42 517-518
-10 miR-524* 1.86E-02 -1.83 19q13.42 517-518
-11 miR-520h 2.20E-02 -1.98 19q13.42 517-518
-12 miR-516-3p 2.20E-02 -1.81 19q13.42 517-518
-13 miR-519d 2.20E-02 -1.78 19q13.42 517-518
-14 miR-371-3p 2.34E-02 -3.58 19q13.42 517-518
-15 miR-455 2.88E-02 -1.88 9q32 -
-16 miR-520b 2.96E-02 -1.85 19q13.42 517-518
-17 miR-518d 3.28E-02 -2.09 19q13.42 517-518
-18 miR-624 3.28E-02 -1.56 14q12 -
-19 miR-296 3.59E-02 -1.85 21q22.12 -
-20 miR-16 4.69E-02 -1.83 13q14 15a-16
Positive values are up-regulated in MM and negative values down-regulated. MicroRNAs in common with Zhou et al [11] are denoted in red font and Pichiorri et
al [12] in bold font.
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Figure 2 Validation of microarray data by qRT-PCR. Expression levels of (A) miR-21, (B) miR-15a, (C) miR-16, (D) miR-221, (E) miR-222, (F) miR-
200b, (G) miR-19a and (H) miR-342 in MM (n = 33), control (n = 9) and MGUS (n = 5) samples measured by qRT-PCR. Expression levels of (I) miR-
221, (J) miR-222, (K) miR-15a and (L) miR-16 in MM patients with and without del(13q). P values were calculated by Mann-Whitney independent t-
test.
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(CCND1) and 4p16 (FGFR3) [18]. A comparison
between cases containing an IgH translocation with
those that did not identified seven differentially
expressed (P < 0.05) microRNAs (Table 2). Expression
levels were distinct in MM cases containing the IgH
translocation (Figure 3A), and predicted 24/26 (92%) of
cases by SVM analysis. Seventeen microRNAs were
identified as being associated with the most common
IgH translocation event, t(11;14) (IgH:CCND1) (P <
0.05; Table 2), four of which (miR-375, miR-650, miR-
193a and miR-582) were consistent with other studies
[19,20]. Expression levels of these microRNAs distin-
guished cases with t(11;14) (Figure 3B), and correctly
predicted the presence of this translocation in 24/26
(92%) of cases by SVM analysis. Three cases in our
cohort had the t(4;14) (IgH:FGFR3) translocation. Eight
microRNAs were associated with this translocation (P <
0.05; Table 2), three of which (miR-99b, miR-342 and
miR-214) were previously identified [19,20]. Expression
levels of these microRNAs distinguished cases with the t
(4;14) translocation (Figure 3C) and correctly predicted
all cases containing this translocation. Interestingly, four
of the six up-regulated microRNAs are encoded on
either chromosome 4 or 14 (miR-376a (14q33.21), miR-
342 (14q32.2), miR-574 (4p14) and miR-577 (4q26)),
and of the two microRNAs (miR-520c and miR-376a)
aberrantly expressed in both t(4;14) and t(11;14) cases,
the latter is encoded proximal to the IgH breakpoint
region at 14q32.
A comparison between microRNA expression in del
(13q) MM patients with patients not harboring this
deletion identified 28 microRNAs by ANOVA (P < 0.05;
Table 2). Expression levels of these microRNAs distin-
guished cases that were del(13q) by cluster analysis (Fig-
ure 3D), and correctly predicted its presence in 22/26
(85%) of cases by SVM analysis. Eight of these micro-
RNAs were consistent with research by Gutiérrez and
colleagues [19], including down-regulation of miR-15a
and miR-16, encoded within the 13q14 locus (Figure 2K
and 2L respectively).
MicroRNA expression is associated with clinical
parameters and survival
The most common paraprotein isotypes associated with
MM are IgG (60%) and IgA (24%) [21]. It has been
reported that IgA myeloma has a poorer prognostic out-
come than patients with IgG myeloma [22], although it
should be noted that we (data not shown) and others
[23] did not find any survival differences between iso-
types. Consequently we compared expression levels
between thirteen cases of IgG-type MM with eight cases
of IgA-type. This resulted in the identification of
twenty-one differentially expressed microRNAs (P <
0.05; Additional file 1 Table S5). Expression levels of
these microRNAs were distinct between IgA and IgG
MM cases (Additional file 1 Figure S4), and correctly
predicted isotype for 20/21 (95%) of cases by SVM
analysis.
Approximately 10% of MM patients secrete only light
chains instead of the complete immunoglobulin mole-
cule [21]. So called “light chain only myeloma” or
“Bence Jones myeloma” had been reported to have a
poorer prognostic outcome [22,24] although a more
recent (and comprehensive) study found no such differ-
ence [23]. In our cohort eight MM cases had light chain
only myeloma. Twenty-seven microRNAs were identi-
fied as being differentially expressed compared to non-
light chain only MM cases (Additional file 1 Table S6).
Expression levels of these microRNAs correctly pre-
dicted light-chain only myeloma in all cases.
As we had successfully identified microRNAs asso-
ciated with clinical outcome in diffuse large B-cell lym-
phoma [7], we assessed differences in microRNA
expression between poor outcome and good outcome in
MM cases, using event-free survival (EFS) as our clinical
criterion (median follow-up = 20 months). Samples
from patients with event-free survival (n = 21) were
contrasted with those from patients who had relapsed
or died in this interval (n = 7). Thirty-two microRNAs
were identified as being differentially expressed (P <
0.05) (Additional file 1 Table S7). These microRNAs
correctly predicted relapse in 24/28 (86%) of cases by
SVM analysis. To investigate the effect of individual
microRNA expression levels on clinical outcome we car-
ried out log-rank (univariate) survival analysis and found
that low expression of miR-153, miR-490, miR-455, miR-
642, miR-500, and miR-296, and high expression of miR-
548d, miR-373, miR-554 and miR-888 were associated (P
< 0.05) with EFS (Figure 4).
Discussion
In this study we used microarray technology to elucidate
the complete miRNome (miRBase version 13.0) of puri-
fied PCs from 33 MM and 5 MGUS patients and com-
pared their expression with counterpart normal PCs.
One hundred and twenty-nine microRNAs were identi-
fied as being aberrantly expressed in MM. Thirty-nine
(30%) of these were previously reported to be aberrantly
expressed in MM by Pichiorri et al [12] and/or Zhou et
al [11]. The reason for these discrepancies probably
reflects the use of differing statistical, microarray and
sampling methods. Of note the former study only exam-
ined 10 MM and 4 controls, whilst the latter study
included only 2 controls for analysis. Consistent with
the findings of Pichiorri and colleagues we found that
miR-21 was up-regulated in both MM and MGUS as
were all seven microRNAs encoded by miR-17-92 clus-
ter (average fold-change = 2.1; range 1.75-2.78).
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Table 2 MicroRNAs associated (P < 0.05) with different genetic subtypes depicting chromosomal location.
Cytogenetic group microRNA Fold change P-value Chromosome
IgH trans (n = 14) miR-590 3.28 1.62E-02 7q11.23
miR-886 1.63 1.46E-02 5q31.1
miR-33b 1.48 2.46E-02 17p11.2
miR-184 -1.43 3.87E-02 15q25.1
miR-139 -1.44 1.47E-02 11q13.4
miR-508 -1.63 4.55E-03 Xq27.3
miR-579 -1.66 2.43E-02 5p13.3
t(11;14) (n = 8) miR-202* 2.16 3.10E-03 10q26.3
miR-520c 2.05 1.26E-03 19q13.42
miR-890 2.04 4.39E-02 Xq27.3
miR-582 1.91 4.06E-02 5q12.1
miR-122a 1.88 1.40E-02 3p21.31
miR-526b* 1.86 1.09E-04 19q13.42
miR-375 -1.74 2.04E-02 2q35
miR-543 -1.59 3.46E-02 14q33.21
miR-650 -1.58 4.00E-02 22q11.22
miR-193a -1.51 1.35E-02 17q11.2
miR-147b -1.46 2.76E-02 15q21.1
miR-526a -1.51 4.68E-02 19q13.42
miR-542 -1.56 1.81E-02 Xq26.3
miR-301 -2.22 4.80E-02 17q22
miR-26b -2.62 3.81E-02 2q35
miR-376a -2.63 2.68E-02 14q33.21
miR-21 -2.82 5.19E-03 17q23.1
t(4;14) (n = 3) miR-376a 3.48 1.23E-02 14q33.21
miR-574 3.11 1.23E-02 4p14
miR-99a 2.53 1.23E-02 21q21.1
miR-214 2.12 2.77E-02 1q24.3
miR-577 1.97 3.85E-02 4q26
miR-342 1.79 3.50E-02 14q32.2
miR-935 -2.07 3.55E-02 19q13.42
miR-520c -2.23 3.85E-02 19q13.42
13q(del) (n = 6) miR-221 -9.71 1.18E-04 Xp11.3
miR-222 -9.50 1.78E-03 Xp11.3
let-7b -5.15 3.38E-03 22q13.31
let-7a -4.92 3.72E-03 9q22.32/11q24.1
let-7c -4.86 6.70E-03 21q21.1
miR-15a -4.42 6.39E-03 13q14
miR-20a -4.41 1.47E-03 13q31
miR-107 -4.40 3.23E-03 10q23.31
miR-26a -4.37 3.26E-03 3p22.2/12q14.1
miR-103 -4.30 8.98E-03 5q34/20p13
miR-142 -4.13 1.15E-03 17q22
miR-195 -3.97 6.98E-03 17p13.1
miR-146a -3.92 1.46E-03 5q33.3
miR-23a -3.80 6.44E-03 19p13.12
miR-92a -3.77 3.57E-03 13q31
miR-27a -3.58 2.25E-03 19p13.12
miR-361 -3.46 4.19E-03 Xq21.2
miR-145 -3.43 7.10E-03 5q32
miR-92b -3.37 9.82E-03 13q31
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However unlike that study, although miR-32 and miR-
181a were identified as being up-regulated by microar-
ray analysis, we failed to find any significant difference
in expression levels by qRT-PCR (data not shown). Sur-
prisingly 10 of the 20 down-regulated microRNAs iden-
tified in the current study are encoded by the miR-371-
1323 cluster located at 19q13.42. This cluster consists of
49 microRNAs, 39 of which were present on our micro-
array. All members of this cluster were down-regulated
(average 1.6-fold; range 1.1-2.5). Interestingly, members
of this cluster (miR-373 and miR-520c) have been
demonstrated to be associated with tumor invasion and
metastasis [25].
The vast majority (109/129 (85%)) of microRNA aber-
rantly expressed in MM were up-regulated, consistent
with the findings of Zhou et al [11]. We [7,26] (and
others[27]) found the same pattern in other B-cell
malignancies. In contrast, we [10] (and others [28])
recently demonstrated that T-cell malignancies are asso-
ciated with a global decrease in microRNA expression.
This suggests a fundamental difference in microRNA
biogenesis between B and T-cell malignancies. A possi-
ble explanation for this distinction comes from our pre-
vious observation that components of the microRNA
biosynthetic pathway (i.e. the microprocessor complex
(DGCR8 and Drosha)) are up-regulated in B-cell malig-
nancies (including MM) but down-regulated in T-cell
malignancies [29].
Using the same array as in this study, we previously
identified 60 and 119 microRNAs aberrantly expressed
in diffuse large B-cell lymphoma (DLBCL) [7] and Séz-
ary syndrome (SzS) (T-cell lymphoma) respectively [10].
A comparison with MM-associated microRNAs revealed
that 25/60 (42%) and 47/119 (40%) of microRNAs
Figure 3 MicroRNA expression can distinguish between different genetic subtypes of MM. Cluster analysis heat maps depicting
expression levels of microRNAs associated with (A) IgH translocation, (B) t(11;14), (C) t(4;14) and (D) del(13q).
Table 2 MicroRNAs associated (P < 0.05) with different genetic subtypes depicting chromosomal location. (Continued)
miR-19a -3.36 5.57E-03 13q31
miR-199a* -2.93 5.93E-03 19p13.2/1q24.3
miR-34a -2.89 2.56E-03 1p36.22
miR-188 -2.79 8.43E-03 Xp11.23
miR-196a -2.40 5.60E-03 17q21.32
miR-485 -2.33 4.18E-03 19q13.42
miR-16 -2.23 7.79E-03 13q14
miR-493 -1.89 2.46E-03 14q32.2
Comparison between MM cases with (positive fold change) and without (negative fold change) chromosomal abnormality as indicated in text. MicroRNAs also
identified by Gutiérrez et al [19] or Lionetti et al [20] are depicted in bold type.
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aberrantly expressed in DLBCL and SzS respectively
were also aberrantly expressed in MM (Figure 5 andAd-
ditional file 1 Table S2). Fourteen microRNAs were dys-
functionally expressed in all three lymphoma types with
miR-223 and miR-143 commonly down-regulated and
miR-574 commonly up-regulated. Although this analysis
is by no means exhaustive this suggests the presence of
a common lymphoma microRNA signature. Down-regu-
lation of miR-223 also has been demonstrated in hepa-
tocellular carcinoma [30], acute myeloid leukemia [31]
and chronic lymphocytic leukemia [32,33], and shown
to regulate the important hematopoietic regulator
LMO2 [34] that is commonly expressed in lymphoma
[35]. Similarly, miR-143 has been reported to be com-
monly down-regulated in hematological malignancy
[36]. We are currently investigating expression of these
microRNAs in a range of lymphoma types to see if their
dysregulation is truly a common feature of lymphoma.
MGUS has been shown to consistently proceed the
development of MM [37] and as such is considered to
represent a pre-malignant model for MM pathogenesis.
Figure 4 Kaplan-Meier survival curves of EFS in MM patients
based on high or low (median) expression levels of microRNAs
(P < 0.05). Curves were compared by univariate (logrank) analysis.
(A) miR-153, (B) miR-490, (C) miR-548d, (D) miR-455, (E) miR-373, (F)
miR-642, (G) miR-554, (H) miR-500, (I) miR-888 and (J) miR-575. Figure 5 MicroRNAs commonly dysfunctionally expressed in
multiple lymphoma types. (A) Venn diagram showing relationship
between microRNAs aberrantly expressed in diffuse large B-cell
lymphoma (DLBCL) [7], Sezary syndrome (SzS) [10] and multiple
myeloma (MM) ((Table 1) (Additional file 1, Table S2)). (B) Tables of
microRNAs aberrantly expressed in all lymphoma types depicting
fold change relative to normal counterpart controls.
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Twenty-three of the 39 (59%) microRNAs aberrantly
expressed in MGUS were also aberrantly expressed in
MM (Additional file 1 Table S3) suggesting common
microRNA expression events in MM progression.
Thirty-seven microRNAs were identified as being differ-
entially expressed between MGUS and MM (Additional
file 1 Table S4), only 9 of these were also differentially
expressed in MGUS compared to controls (i.e. specific
for MGUS) including miR-21 as previously identified
[12]. The relationship between microRNAs dysfunction-
ally expressed in MGUS and MM are shown in Addi-
tional file 1 Figure S3. miR-21 over-expression has been
linked to an anti-apoptotic phenotype and enhanced
tumor growth [38,39] and as such may represent an
important aberration in the early pathogenesis of MM.
Next we investigated the identity of microRNAs asso-
ciated with the major genetic subtypes of MM. Two
previous studies by Lionetti et al [20] and Gutiérrez et
al [19] have also examined microRNA expression asso-
ciated with recurrent chromosomal abnormalities in
MM. Generally our findings were consistent with these
studies although microRNAs associated with specific
abnormalities did not always completely overlap. The
cause for discrepancies between studies, including lack
of concordance between the two previously published
studies, again probably represents differences between
microarray platforms, statistical techniques and samples
used for analysis. For example the study of Gutiérrez et
al considered cases in which del(13q) was the sole chro-
mosomal abnormality and deregulated microRNAs were
identified on the basis of their expression relative to
control PCs, whereas our study and that of Lionetti et
al considered the difference between MM cases with
and without specific chromosomal abnormalities [19,20].
The latter study considered genetic abnormalities in the
context of a gene-expression defined molecular translo-
cation/cyclin (TC) classification system [20]. Such differ-
ences between studies are a reflection of the relative
immaturity of the microRNA field that has only formally
existed for the last 9 years, and is something that will
surely be resolved in future years.
Interestingly, from the 28 microRNAs associated with
the presence of del(13q), all seven microRNAs encoded
by the miR-17-92 cluster (encoded at 13q31) were
down-regulated (average 3.1 fold; range 1.2-4.1). Recent
data suggests that unlike the characteristic del(13q) kar-
yotype observed in chronic lymphocytic leukemia (CLL)
defined by loss of the 13q14 locus, the minimal deleted
region of 13q loss in MM extends from 13q14 to the
13q34 locus [40], consistent with down-regulation of the
miR-17-92 cluster observed in these cases. Although
down-regulation of the miR-17-92 cluster was also
reported by Gutiérrez et al [19], this finding is counter-
intuitive as members of this cluster are widely believed
to function as oncogenes [41] whilst the presence of del
(13q) is associated with an adverse prognostic outcome
in MM [42]. A possible explanation for this apparent
paradox is that although widely up-regulated in a wide
range of cancers [9,26,43], the miR-17-92 cluster has
been proposed to act as both tumor-suppressor or onco-
gene depending upon the cellular context [44-46].
Recently we reported that this cluster is down-regulated
in T-cell lymphoma where it was shown to have tumor-
suppressor properties [10]. Consequently, it is possible
that the cluster is similarly acting as a tumor-suppressor
in del(13q) MM cases although it should be noted that
up-regulation of this cluster is associated with MM diag-
nosis (Table 1) and at least one member of this cluster
(miR-19) was found to antagonize MM tumor develop-
ment in a murine model [12].
We also report for the first time a correlation between
microRNA expression and isotype in MM including the
presence of light-chain only myeloma. Such information
might be useful in providing an alternative clinical clas-
sification of new MM patients. Finally, we examined
how the expression levels of individual microRNAs
might influence clinical outcome of MM patients by
correlating expression values with adverse effects using
Kaplan-Meier survival analysis. We found that high
expression of miR-153, miR-490, miR-455, miR-642,
miR-500, and miR-296 were associated with better EFS
in our cohort of patients whilst the opposite was true
for miR-548d, miR-373, miR-554 and miR-888. Interest-
ingly, the most discriminatory of these microRNAs (i.e.
miR-153) has been shown to target BCL2 and MCL1
[47] and that over-expression of both of these are asso-
ciated with poor prognostic outcome in MM [48]. Low
expression of miR-455 has also been associated poor
overall survival in endometrial serous adenocarcinoma
[49], and low levels of miR-296 shown to be associated
with increased prostate tumor growth and invasion
properties via targeting of HMGA [50]. It should be
noted however that these data need to be tested in an
independent test cohort before any firm conclusions can
be drawn about the prognostic ability of these micro-
RNAs in MM patient survival, whilst the current results
provide the experimental basis for future validation
experiments.
Conclusions
In summary, these results indicate that aberrant expres-
sion of microRNAs is a common feature of MM as well
as pre-malignant MGUS, and that this phenomenon is
associated with genetic and clinical subtype as well as
clinical outcome. This data reinforces the complex nat-
ure of MM and hopefully will provide useful informa-
tion in clarifying the molecular basis of this disease in
future studies.
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Methods
Patient samples and cell lines
Bone marrow samples were obtained from patients
attending the Department of Haematology, John Rad-
cliffe Hospital, Oxford, UK or Dubrava University hospi-
tal Zagreb, Croatia. Patients were diagnosed as MM (n
= 33) or MGUS (n = 5) according to criteria described
in the myeloma management guidelines [51]. The med-
ian age of patients was 67 yrs (range 43-89 yrs). Indivi-
dual patient details are shown in Additional file 1 Table
S1. Plasma cells (PC) were purified from bone marrow
aspirates by positive immunomagnetic selection (CD138
+) according to manufacturer’s instructions (Miltenyi
Biotec, Bisley, UK). PCs obtained from the bone marrow
of nine healthy individuals were used as controls. The
purity of PC samples was > 90% CD138+ as measured
by immunohistochemical staining.
Patient samples were collected in accordance with the
Declaration of Helsinki and approved by the local ethics
committee (Oxforshire Regional Ethics Committee; Ref
no. 07/Q1606/25). Patients gave written informed con-
sent for the sample collection.
MM cell lines, NCI-H929, JJN3, RPMI8226 and Thiel
were routinely cultured in RPMI 1640 containing 10%
fetal calf serum (Invitrogen, Paisley, UK). All cell lines
were obtained from the DSMZ cell collection
(Braunschweig, Germany) except Thiel which was a
kind gift from Prof. Diehl (University of Cologne,
Germany).
Cytogenetic classification of myeloma samples
Purified MM patient PCs (~105 cells) were classified
according to cytogenetic criteria using the micro-FISH
technique as previously described [17]. The following
probe sets obtained from Vysis (Abbott Diagnostics,
Maidenhead, UK) were used for classification; D13S319
Spectrum-Orange/LSI-13q34-Spectrum-Green (del(13q)
probe), IgH Spectrum-Green/FGFR3 Spectrum-Orange
(t(4;14) fusion probe), IgH Spectrum-Green/CCND1
Spectrum-Orange (t(11;14) fusion probe), and IgH dual-
color (Spectrum-Green/Spectrum-Orange) break-apart
probe [52]. At least 100 nuclei were scored for each
probe. A 20% cut-off was used for numerical abnormal-
ities and 10% for fusions and break-apart probes as
recommended by the European Myeloma Network FISH
workshop guidelines http://www.myeloma-europe.org.
RNA purification and microarray analysis
MicroRNA was isolated from samples (~106 cells) using
Trizol (Invitrogen, Paisley, UK) and RNeasy columns as
described by the manufacturer (Qiagen, Crawley, UK).
MicroRNA (~500 ng) were labeled and hybridized to
μRNA microarrays as previously described [26] using
tonsillar material (pooled from twelve healthy indivi-
duals) as a common reference in a dye-balanced design.
The arrays contained 655 human probes (miRBase
v.10.1). Probe details can be found at http://www.micro-
RNAworld.com.
Image analysis was carried out with BlueFuse software
(BlueGnome, Cambridge, UK). Raw image data were
global loess-normalized within arrays and normalized
between arrays using the LIMMA package [53]. The
normalized log ratios (average of four replicates per
probe) were used for subsequent analysis in Genespring
7.2 (Agilent Technologies, CA, US). ANOVA analysis
was used to identify microRNAs differentially expressed
between sample types and P values were adjusted using
the Benjamini-Hogberg correction method. Differentially
expressed genes were tested for their ability to predict
sample class using the leave-one-out cross-validation
support vector machine (SVM) function in Genespring
(Polynomial Dot Product (Order 1) Kernel Function.
Diagonal Scaling Factor: 0). All microarray data was
MIAME compliant and raw data has been deposited in
the GEO database (Accession series # GSE243371).
Quantitative RT-PCR (qRT-PCR)
MicroRNA qRT-PCR was carried out using Taqman
probes as described by the manufacturer (Applied Biosys-
tems, Warrington, UK) using 20 ng of microRNA per
reaction in a Roche LightCycler 480 machine. Triplicate
samples were used throughout. The mean Ct value of
each triplicate was used for analysis, by the ΔCt method
(ΔCt = mean Ct of microRNA of interest-mean Ct of U6).
Expression levels were compared using Mann-Whitney
independent t-test (Graphpad Prism v.4.0, La Jolla, CA).
Survival analysis
Kaplan-Meier survival analysis was carried out on event
free survival (EFS) times of MM patients as a function
of microRNA expression, using the median value as cut-
off. EFS was calculated as the time of diagnosis to the
date of clinical relapse, death or last contact. Patients
who were relapse-free at time of last contact were cen-
sored for analysis. Mean follow-up time was 20 months
(range 1-60 months). Curves were compared by univari-
ate (logrank) analysis using GraphPad Prism version
4.00 (La Jolla, CA).
Reviewers’ comments
Reviewer #1: Prof. Neil Smalheiser, Department of Psy-
chiatry, University of Illinois, Chicago, IL, US.
Reviewer’s comments
This is a nice paper and I only have relatively minor
comments, which can be addressed by page number:
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p. 2. It would not hurt to have some discussion of the
miR expression in the control group, in terms of the cell
type profile, heterogeneity across individuals, etc. If you
included that, I missed it.
Authors’ response
Whilst the reviewer has an interesting suggestion i.e. to
look at variation in miRNA expression across the control
group, the main theme of this research was to look at
expression in multiple myeloma, therefore the number of
controls samples used (n = 9) does not have sufficient
power in order to address that specific question. How-
ever, our data does suggest that the control samples var-
ied little in their miRNA expression profile as shown by
unsupervised cluster analysis (Figure 1).
p. 2. You speak of altered miR expression in tumor
cells as “aberrant” throughout the paper. Yet not every
difference is necessarily aberrant. Some changes may be
compensatory; some changes may simply reflect the
physiological state of the tumor cells without being
linked to tumorigenicity per se (e.g., they may differ in
O2 tension or pH).
Authors’ response
We whole-heartedly agree that not all differentially
expressed miRNAs identified in MM tumor cells will be
directly linked with their neoplastic nature but instead
may reflect indirect effects such as their abnormal micro-
environment and/or interaction with non-tumor cells for
example. We believe however that as these effects, direct
and indirect, cumulatively represent tumor-associated
changes in the miRNA expression profile of cells, that the
use of the adjective ‘aberrant’ in this context is an accu-
rate description of the expression behavior of miRNAs
that are ‘diverging from the normal’ (Oxford Concise
Dictionary).
p. 10 and Methods. It is worthwhile to describe the
method of correcting p-values for multiple-testing in
more detail.
Authors’ response
As stated in the methods section p-values were corrected
using the Benjamini-Hogberg multiple testing correction
algorithm as implemented in the ANOVA function of the
Genespring software package. This algorithm is based on
false discovery rate error type and further details can be
found in the original publication of this method (Benja-
mini and Hochberg (1995). Journal of the Royal Statisti-
cal Society B, 57, 289-300)). As this method is widely
used in microarray analyses we believe that a more in-
depth and mathematical description of this method is
not warranted for this manuscript.
p. 10 and throughout. The paper has a nice balance
between considering miRs as a clinical tool and as an
indication of tumor biology. However, you can go still
further to analyze in biological terms WHY the pat-
tern of altered miR expression is the way it is, or
(stated a different way) to analyze what dimensions
are most important for SVM prediction. For example,
do the altered miRs all share the same TFs driving
them?
Authors’ response
The reviewer has raised a very important point about
addressing the reason for aberrant miRNA expression in
MM. However, the causal mechanisms behind miRNA
dysregulation in any cancer are complex, although we
did try to proffer some insight in the context of MM in
both results and discussion sections of this manuscript.
Possible mechanisms include chromosomal lesions at
miRNA-encoding regions and defects in miRNA biosyn-
thetic machinery, both of which were addressed in this
manuscript. Further mechanisms include epigenetic regu-
lation, changes in expression of genes such as E2F that
can bind to promoter regions of pri-miRNA sequences, as
well as any factor that can regulate levels of the protein-
encoding genes that encode for >40% of human miRNAs.
The problem with identifying genes such as TFs that are
potentially targeted by commonly differentially expressed
miRNAs, is that currently the predictive algorithms to
carry out this type of analysis perform very poorly
(Sethupathy, et al (2006) Nat Methods, 3, 881-886).
Therefore we believe that the robustness and hence use-
fulness of such an in silico approach is limited. Conse-
quently we decided to restrict our discussion to those
target genes that have been independently experimentally
validated.
p. 13. You mention that dicer and drosha tend to be
up-regulated in B-cell malignancies. It would be desir-
able to have measured these in the SAME samples
reported here and see if dicer and/or drosha levels are
tightly correlated with miR up-regulation.
Authors’ response
This would be the ideal situation, and in the case of the
DLBCL case this comparison was carried out (Lawrie et
al (2009) Br. J. Haematol., 145, 545-548). Unfortunately
there was insufficient material left from the current
study to carry out a similar analysis on the MM
samples.
p. 19, Methods. Were control and tumor samples col-
lected during the same period? stored for similar
amounts of time? Assayed in parallel? If not, this could
create confounds.
Authors’ response
Due to the logistics of obtaining bone marrow samples
from ~50 patients/controls it would have been extremely
difficult to collect samples over the same period- samples
were collected over a ~2 year period from two centers
(Oxford and Zagreb). Patient/control samples were
assayed in parallel and randomized/anonymized to the
researchers processing them in order to minimize con-
founding variables.
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p. 20, Methods. Was U6 expression the same in con-
trol and tumor samples? This should be stated explicitly.
Authors’ response
U6 levels were measured in controls and tumor in paral-
lel using the same assay system (i.e. Taqman probe qRT-
PCR). There was no significant difference in absolute U6
expression levels (i.e. Ct values) between controls and
tumor samples.
p. 29, Table 1. You have mir-200a listed twice with
two different values?! Please check this (very long) table.
Authors’ response
This was a mistake. Position 25 in Table 1should have
read miR-200a* and not miR-200a, this has been
corrected.
p. 35, Figure 3 Legend. Please spell out DL, MM and
SZ
Authors’ response
This issue has been addressed.
Reviewer #2: Prof. Yuriy Gusev, Department of Sur-
gery, University of Oklahoma, OK, USA.
This reviewer provided no comments for publication.
Reviewer #3: Unknown reviewer
Reviewer’s comments
This manuscript includes a description of microarray
analysis for the expression of microRNA in purified
CD138+ cells from 33 patients with multiple myeloma
(MM), 5 patients with monoclonal gammopathy of
undetermined significance (MGUS), and 9 healthy
volunteers. The authors found distinct microRNA
expression profiles from each group. Similar studies
from 2 different groups have been reported. However, in
one study only 16 samples from patients with MM, 6
from patients with MGUS, and 6 controls were included
and in the another study samples from 52 patients but
only 2 controls were studied. The manuscript is clear
and concise. The data are convincing and the area of
investigation is important. This manuscript is a valuable
contribution. Specific comments follow:
1. The authors state several times that they have per-
formed a comprehensive study to elucidate the complete
miRNome of the CD138+ cells; however, I could not
find how “complete” was defined. The manuscript
would be improved by including a consideration about
the completeness of the analysis performed. How the
microarray analysis was defined as a complete analysis
of miRNA and citations would enhance the manuscript.
Authors’ response
The ‘complete miRNome’ refers to the microarrays
(μRNA microarrays) used for these experiments which
contain probes against every known miRNA (the miR-
Nome) as defined by the reference depository for miRNAs
(miRBase- http://www.mirbase.org) (Griffiths-Jones et al
(2006), Nucleic Acids Research, 34, D140-144). At the
time when these experiments were started (June 2009),
the miRBase version was 13.0 which included 655
human sequences. The authors readily accept that the
miRNA database has grown since this time and that the
current version of the miRBase miRNome is version 16
and contains 1048 human sequences. This assertion has
been modified in the text to read ‘complete miRNome
(miRBase version 13.0)’ in the text in order to avoid
confusion.
2. The “leave-one-out cross-validation support vector
machine algorithm” (mentioned on page 7) is not
defined or described in the methods section. The sup-
port vector machine algorithm is also mentioned in the
abstract but the manuscript would be improved by
describing and referencing this technique.
Authors’ response
The support vector machine (SVM) algorithm is a super-
vised learning method commonly used for classification
in microarray experiments (along with k-nearest neighbor
algorithm) and is based on non-probabilistic binary lin-
ear classification (Cortes & Vapnik (1995) Machine
learning, 20). We believe that as the parameters used for
its implementation within the Genespring package as
described in the materials and methods section are
already given, that this would be sufficient information
for others to carry out the same analysis.
3. In the results the authors state that 8 miRNA were
chosen to be measured by qRT-PCR to validate the
microarray data. They state, “These data were consistent
with the microarray results”. In the discussion the
authors indicate that “miR-32 and miR-181a were iden-
tified as being up-regulated by microarray analysis” by
qRT-PCR failed to show any significant differences in
expression levels. Were there other miRNA studied by
qRT-PCR? Why weren’t miR-32 and miR181a included
in Figure 2?
Authors’ response
The eight miRNAs that were tested by qRT-PCR shown
in Figure 2were chosen on the basis that they were differ-
entially expressed in our microarray analysis and had
previously been shown to be dysregulated in MM or
other hematological malignancies. As all of these miR-
NAs were also significantly differentially expressed when
measured by qRT-PCR they were described as being ‘con-
sistent with the microarray data’. The only other miR-
NAs that we measured (miR-32 and miR-181a) by qRT-
PCR which were also chosen on the basis shown to be
dysregulated in previous studies but we did not find
them to be significantly different by qRT-PCR which is
why the data was not included in Figure 2.
4. In the discussion the authors state that the investi-
gators of reference 17 “only examined 10 MM and 4
controls”. In the abstract of this manuscript, Pichiorri et
al. indicate that 16 samples from patients with MM
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were studied along with 6 with MGUS and 6 normal
donors. Also, in this same spot of the discussion, the
authors indicate that the investigators of reference 16
only studied 2 controls but the 52 patient samples ana-
lyzed was not mentioned. Moreover, the purpose of that
study was to risk stratification.
Authors’ response
These comments in the discussion were made in the con-
text of the identification of aberrantly expressed miRNA
associated with MM diagnosis. The Pichiorri study states
in the results section (pg 12886) that their MM-asso-
ciated miRNA signature was derived from the array
data of 41 MM cell lines, 10 MM patients and 4 con-
trols. Whereas for the Zhou et al study (pg 7904) the
MM miRNA signature was derived from a comparison of
array data from 52 MM cases with samples from 2
healthy donors. Whilst it is true that the Zhou et al
study mainly focused on the identification of risk groups
within the 52 MM cases, a significant part of the results
section of this paper refers to the identity of miRNAs
that are differentially expressed between controls and
MM cases. The point that we were making in the discus-
sion is that insufficient numbers of controls were used in
both of these previous studies, and that our study was
therefore an improvement on these studies, in the context
of the identification of aberrantly expressed miRNAs in
MM tumor cells.
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Information About a Microarray Experiment; MM: multiple myeloma; PC:
plasma cell; qRT-PCR: quantitative reverse transcriptase polymerase chain
reaction; RB1 - retinoblastoma 1; SVM: support vector machine; SzS: Sezary
syndrome;
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